• 1
    Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol1996;27:567574.
  • 2
    Verma S, Anderson TJ. The ten most commonly asked questions about endothelial function in cardiology. Cardiol Rev2001;9:250252.
  • 3
    World Health Organization. Causes of death 2008: Data sources and methods. Geneva 2010. Available from: [Accessed 6 July 2011].
  • 4
    Worrall G. Results of the DCCT trial. Implications for managing our patients with diabetes. Can Fam Physician1994;40:19551960.
  • 5
    Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group 1. BMJ1998;317:703713.
  • 6
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med1993;329:977986.
  • 7
    D’Elia JA, Bayliss G, Roshan B, Maski M, Gleason RE, Weinrauch LA. Diabetic microvascular complications: Possible targets for improved macrovascular outcomes. Int J Nephrol Renovasc Dis2011;4:115.
  • 8
    American Diabetes Association. Standards of medical care in diabetes – 2010. Diabetes Care2010;1(Suppl):S11S61.
  • 9
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352:837853.
  • 10
    Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008;358:25452559.
  • 11
    Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008;358:25602572.
  • 12
    Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol2002;31:150153.
  • 13
    Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924926.
  • 14
    Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J2008;155:2632.
  • 15
    Shikata K, Haneda M, Koya D, et al. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design. Diabetes Res Clin Pract2010;87:228232.
  • 16
    Lapina I, Filatov DN, Mareev VI, et al. Effect of strict glycemic control on clinical state and course of the disease in patients with chronic heart failure and type II diabetes mellitus. Results of the REMBO “rational effective multicomponent therapy in the struggle against diabetes mellitus in patients with congestive heart failure” study. Kardiologiia2008;48:1727.
  • 17
    Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet1998;352:854865.
  • 18
    Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18:11131123.
  • 19
    Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med2009;360:129139.
  • 20
    Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care2000;23(Suppl 2):B21B29.
  • 21
    Hong W, Mao-jin X, Da-jin Z, Qiao-jun H, Xue H. Intensive glycemic control and macrovascular events in type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Chin Med J2010;123:29082913.
  • 22
    Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med2009;151:394403.
  • 23
    Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: A meta-analysis. Nutr Metab Cardiovasc Dis2009;19:596603.
  • 24
    Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis2009;19:604612.
  • 25
    Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: A systematic review and meta-analysis. Diab Vasc Dis Res2010;7:119130.
  • 26
    Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet2009;373:17651772.
  • 27
    Tkac I.Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials. Diabetes Res Clin Pract2009;86(Suppl 1):S57S62.
  • 28
    Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet2005;366:12791289.
  • 29
    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003;348:383393.
  • 30
    Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet2007;370:11291136.
  • 31
    Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care2005;28:15471554.
  • 32
    Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care2007;30:24582464.
  • 33
    Davidson M, Meyer PM, Haffner S, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation2008;117:21232130.
  • 34
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA2007;298:11801188.
  • 35
    Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab2008;10:12211238.
  • 36
    Nagajothi N, Adigopula S, Balamuthusamy S, et al. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: A meta-analysis of randomized, controlled trials. Am J Ther2008;15:506511.
  • 37
    Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med2008;168:20702080.
  • 38
    Perez A, Kupfer S SR. Pioglitazone treatment is associated with reduced cardiovascular ischemic events in type 2 diabetic patients with high or low cardiovascular risk. Diabetes2008;57(Suppl 1):A155A156.
  • 39
    Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet2009;373:21252135.
  • 40
    Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med2008;168:23682375.
  • 41
    Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med2007;147:578581.
  • 42
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med2007;356:24572471.
  • 43
    Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med2007;357:6769.
  • 44
    Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA2007;298:11891195.
  • 45
    Thiazolidinedione intervention with vitamin D evaluation (TIDE) identifier: NCT00879970. 2011.
  • 46
    Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med2010;363:14101418.
  • 47
    Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909.